Compare LIQT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | TVRD |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 27.5M |
| IPO Year | 2011 | 2013 |
| Metric | LIQT | TVRD |
|---|---|---|
| Price | $0.57 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.30 | ★ $29.50 |
| AVG Volume (30 Days) | 121.3K | ★ 339.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | $42.12 | N/A |
| Revenue Next Year | $63.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.52 | $1.50 |
| 52 Week High | $3.35 | $43.65 |
| Indicator | LIQT | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 40.71 |
| Support Level | N/A | $1.70 |
| Resistance Level | $0.74 | $2.04 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 19.57 | 52.97 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.